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Parkinson disease (PD) is a neurodegenerative disorder characterized by motor and non-motor symptoms which
relentlessly and progressively lead to substantial disability and economic burden. Pathologically, these symptoms follow the loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) associated with
abnormal α-synuclein (α-Syn) deposition as cytoplasmic inclusions called Lewy bodies in pigmented brainstem
nuclei, and in dystrophic neurons in striatal and cortical regions (Lewy neurites). Pharmacotherapy for PD
focuses on improving quality of life and primarily targets dopaminergic pathways. Dopamine acts through two
families of receptors, dopamine D1-like and dopamine D2-like; dopamine D3 receptors (D3R) belong to dopamine D2 receptor (D2R) family. Although D3R’s precise role in the pathophysiology and treatment of PD has not
been determined, we present evidence suggesting an important role for D3R in the early development and
occurrence of PD. Agonist activation of D3R increases dopamine concentration, decreases α-Syn accumulation,
enhances secretion of brain derived neurotrophic factors (BDNF), ameliorates neuroinﬂammation, alleviates
oxidative stress, promotes neurogenesis in the nigrostriatal pathway, interacts with D1R to reduce PD associated
motor symptoms and ameliorates side eﬀects of levodopa (L-DOPA) treatment. Furthermore, D3R mutations can
predict PD age of onset and prognosis of PD treatment. The role of D3R in PD merits further research. This review
elucidates the potential role of D3R in PD pathogenesis and therapy.

1. Introduction
Parkinson disease (PD), the second most common progressive neurodegenerative disorder, aﬀects ∼1 % population over 60 years old
(Macdonald et al., 2018), and is characterized by resting tremor, bradykinesia, rigidity and postural instability (Kalia and Lang, 2015). PD is
typically not diagnosed until motor symptoms develop, although nonmotor manifestations including depression, sleep problems and loss of
smell, typically begin years earlier (Srivanitchapoom et al., 2018).
Current treatment focuses on relief of motor symptoms and no approved treatment slows disease progression. Ideally, disease modifying
interventions should be applied as early as possible. While most pharmacotherapies have focused on dopamine D1 receptor (D1R) and dopamine D2 receptor (D2R) (Lewis et al., 2006), the stimulation in D3R
plays an important role in PD pathogenesis. Thus, D3R may both provide a biomarker for early-stage pathological changes and also

represent a target for development of novel therapeutics. In this communication we review the characteristics of D3R, its role in the pathogenesis of PD and as a potential target for therapeutics.
Dopamine (3-hydroxytyramine, DA) plays a critical part in movement, cognition, emotion, memory, reward, and drug addiction, and
involves in a number of distinct neurodegenerative diseases, in which
PD is the most widely recognized. Early motor manifestations of PD
result from degeneration of nigral dopaminergic cell bodies in the
substantia nigra pars compacta (SNpc) and the subsequent dysfunction
of the terminal ﬁelds of those neurons producing a reduction in striatal
DA (Girault and Greengard, 2004). DA binds to ﬁve closely related yet
functionally distinct G protein-coupled receptors (GPCRs) named dopamine receptors (DRs). These DRs are divided into two major groups:
the D1-like receptors (D1, D5), and the D2-like receptors (D2, D3, D4).
It is commonly believed that D1Rs couple to Gαs/olf and induce production of cyclic adenosine monophosphate (cAMP) and the activation
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Pre & Post (Diaz et al., 2000; Stanwood et al.,
2000)

∼2 (Sanchez-Soto et al., 2016; Scheideler et al.,
1997)
PD128907 (Millan et al., 2000; Scheideler et al.,
1997)
PF-529379 (Collins et al., 2012)

D2s in Pre, D2l in Post (Cooper and Stanford,
2001; Rondou et al., 2010)

∼500 (Rondou et al., 2010)

Lack of

A-77636 (Kebabian et al., 1992)

PD (Beaulieu and Gainetdinov,
2011), HD (Augood et al., 1997;
Bibb et al., 2000),

ADHD (Gizer et al., 2009), MS
(Giorelli et al., 2005)

SCZ (Seeman et al., 2005), Depr (Willner,
1997), PD (Kalia and Kalia, 2015; Prieto et al.,
2011), SA (Le Foll et al., 2009), RSL (Keck
et al., 2015)

N-0437 (Van der Weide et al., 1988)

PD, RLS (Cortes et al., 2016), SCZ (Gross et al.,
2013), SA (Le Foll et al., 2014a), HD (Ariano
et al., 2002), AD (Nakajima et al., 2013), Depr
(Cao et al., 2010)

44.2 kD (Beaulieu and Gainetdinov, 2011)

∼180–400 (Rondou et al.,
2010)
77-LH-28-1 (Del Bello et al.,
2018)
PD168077 (Sampson et al.,
2014)
SCZ (Rondou et al., 2010),
ADHD (Coghill and
Banaschewski, 2009)

387 (Beaulieu and Gainetdinov,
2011)
41.5 kD (Beaulieu and
Gainetdinov, 2011)
53 % with D2R (Missale et al.,
1998)
FrC, AM, Hip, Hypo, GP, SNr,
Thal (Beaulieu and
Gainetdinov, 2011)
Mainly Post (Rondou et al.,
2010)

D4R

Caudate-Putamen (CPu), Prefrontal Cortex (PFC), Nucleus Accumbens (NAc), Olfactory Bulb (OB), Amygdala (AM), Frontal Cortex (FrC), Hippocampus (Hip), Cerebellum (CB), Prefrontal Cortex (PFC), Premotor Cortex
(PMC), Cingulated Cortex (Cg), Entorhinal Cortex (Ent), Hypothalamus (Hypo), Dentate Gyrus (DG), Striatum (Str), Olfactory Tubercle (OTB), Ventral Tegmental Area (VTA), Septum (Sept), Islands of Calleja (IC), Globus
Pallidus (GP), Substantia Nigra pars reticulate (SNr), Thalamus (Thal), Pre-synaptic location (Pre), Post-synaptic location (Post), Restless Legs Syndrome (RLS), Schizophrenia(SCZ), Substance Addiction (SA), Depression
(Depr), Attention Deﬁcit Hyperactivity Disorder(ADHD).

Related diseases

Aﬃnity to DA (Ki value
in nM)
Speciﬁc agonist

SCH23390 (Monti and Jantos, 2018)

NAc, OTB, IC, Str, SNpc, VTA, Hip, Sept (Beaulieu
and Gainetdinov, 2011)

SN, VTA, Str, Hypo, Sept, AM, Hip (Beaulieu
and Gainetdinov, 2011; Mishra et al., 2018)

PFC, PMC, Cg, Ent, SN,Hypo, Hip,
DG, NAc, OTB (Beaulieu and
Gainetdinov, 2011)
Mainly Post (Beaulieu and
Gainetdinov, 2011) and seldom Pre
in PFC in primates (Muly et al.,
2009)
∼225 (Sunahara et al., 1991)

CPu, NAc, SN,OB, AM, FrC, Hip, CB
(Beaulieu and Gainetdinov, 2011;
Mishra et al., 2018)
Mainly Post (Beaulieu and
Gainetdinov, 2011) and seldom Pre
in PFC in primates (Muly et al.,
2010)
∼2500 (Sunahara et al., 1991)

Brain distribution

Synapse location

79 % with D2R (Boeckler and Gmeiner, 2007)

—

49 % with D1R (Grandy et al., 1991)

—

Sequence homology

50.6 kD (Dal Toso et al., 1989)

400 (Beaulieu and Gainetdinov, 2011)

52.9 kD (Grandy et al., 1991)

443 (Dal Toso et al., 1989)

50.5 kD (Wang et al., 2014)

477 (Grandy et al., 1991)

Molecular weight

D3R

452 (Wang et al., 2014)

D2R

Number of amino acids

D5R

D1R

D2Rs

Subtype

D1Rs

Table 1
Structural, distributional and pharmacological properties of DR subtypes.
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2. The D3R regulation in the nigrostriatal regions of PD

of protein kinase A (PKA), while D2Rs activate Gαi/o and inhibit cAMP
production (Beaulieu and Gainetdinov, 2011). These receptors diﬀer in
their distribution, expression, aﬃnity and functional properties (see
Table 1).
DA can not cross the blood brain barrier, so the prodrug levodopa
(L-DOPA) was administered to patients with PD. This therapeutic approach provided dramatic clinical beneﬁt but motor complications like
“on-oﬀ” ﬂuctuations soon limited its clinical application (Wijeyekoon
and Barker, 2009). Subsequently, DR agonists were developed but these
agonists were non-selective or selective only for D1Rs or D2Rs families
(Hori and Kunugi, 2013; Moore et al., 2014). DR agonist therapy is
more prone to produce non-motor side eﬀects that include neuropsychiatric problems such as hallucinations, delusions, impulse control disorders (ICD), cognitive impairment and non-neuropsychiatric
problems such as gastrointestinal symptoms, orthostatic hypotension
and valvular heart diseases (Brusa et al., 2003; Fenelon et al., 2000;
Hori and Kunugi, 2013; Lang, 2001; Poewe, 2003; Voon et al., 2011).
Some of these side eﬀects are related to the lack of subtype speciﬁcity.
Unfortunately, high amino acid sequence homogeneity across DR subtypes creates challenges in developing subtype selective agonists.
Although many studies have focused on D1R and D2R speciﬁc drugs
for PD, D3R may be an appropriate alternative target. Evidence supporting this strategy comes from: 1.) Although the density of D1R and
D2R are 2–3 times higher than D3R density in the striatum of aged
human brain (Sun et al., 2012), DA binds to D3R with more than 100fold higher aﬃnity than it binds to D2R or D1R. Furthermore, therapeutic activation of D3R may be highly relevant since the basal concentrations of DA in extracellular (5–10 nM) and synaptic (50 nM)
spaces (Prieto, 2017) are much lower than the Ki of DA at D1R or D2R,
but higher than its Ki at D3R (see Table 1); 2.) Among all classes of
pharmacological drugs that have been evaluated, D2R/D3R agonists are
considered to be the most eﬀective treatment for motor deﬁcits in PD
(Magnard et al., 2016). However, due to the lack of clearly deﬁned
subtype-selective therapeutics, it is hard to clarify which DR subtype is
responsible for beneﬁcial eﬀects when treating patients with PD
(Magnard et al., 2016). Pramipexole, apomorphine, ropinirole and rotigotine are currently the most commonly used DA agonists. Pramipexole, which was thought to be a D1R&D2R receptor agonist in 1990
(Kaneko et al., 1990), was later found to be a potent D3R agonist (Chen
et al., 2014) and preferentially stimulates D3R compared with D2R
(D2R/D3R selectivity of 24-800) (Cortes et al., 2016) with little aﬃnity
(> 1000 nM) to D1R (Wood et al., 2015). Apomorphine, ropinirole and
rotigotine, ﬁrst reported as D2R agonists (Eden et al., 1990; Umegaki
et al., 1997; Van der Weide et al., 1988), were found to bind to D3R
with 2–4, 19–94 and 19–20 fold higher aﬃnity than D2R (reviewed in
(Cortes et al., 2016)). Thus D3R action of these drugs may be more
important than initially expected, and early studies should be reevaluated.
D3R was ﬁrstly discovered in 1990 (Sokoloﬀ et al., 1990), but initial
researches into its action were hampered due to lack of potent and
selective D3R ligands. D3R belongs to the D2R family and possesses
seven membrane spanning-helices, an intercellular carboxyl terminus,
and an extracellular amino terminus linked with intra and extra-cellular
protein loops (Maramai et al., 2016). D3R is both a presynaptic autoreceptor and a postsynaptic receptor, distinguishing it from most of
other DR types except D2R (see Table 1). Studies indicate that D3R
plays an important role in in the CNS by modulating motor activity,
emotions, memory and reward mechanisms (Beaulieu and Gainetdinov,
2011), thus D3R therapies initially focused on schizophrenia and drug
addiction. Recent studies have addressed the potential involvement of
D3R in PD. Here we review the role of D3R in the pathogenesis,
treatment and prognosis of PD and potential mechanisms underlying its
role in treatment of PD.

2.1. The importance of biomarkers in PD pathogenesis
PD is pathologically deﬁned post-mortem by abnormal α-synuclein
(α-Syn) deposition (Lewy bodies/neurites) in the SNpc, striatal, and
cortical regions, as well as a marked loss of dopamine projection from
SN to striatum (Dauer and Przedborski, 2003; Zhang et al., 2018). The
development of therapies for PD is limited by lacking in objective
markers that show the pathogenesis and severity of PD. Pathologically,
α-Syn is closely related to PD and considerable research eﬀorts were
made to ﬁnd a suitable biomarker for α-Syn. However, no in vivo
imaging biomarkers of α-Syn deposition are currently available. Thus,
detection of α-Syn concentration in bodily ﬂuid is used to evaluate if
they are related to the progression of PD (Fayyad et al., 2019). Blood is
the most accessible bodily ﬂuid but the detection α-Syn in blood has
yielded inconsistent results. Blood tests have given both increased
(Miller et al., 2004) and decreased α-Syn levels (Li et al., 2007) in PD
patients when compared with controls. Most of the results using cerebrospinal ﬂuid (CSF) have shown that total α-Syn is down-regulated in
PD (Fayyad et al., 2019), except one reported no diﬀerences between
PD and control cohorts (Ohrfelt et al., 2009). However, this is a diﬃcult
method to apply clinically, because cerebrospinal ﬂuid is obtained by
lumbar puncture which is especially hard for elderly PD patients. As a
result, researchers have turned their attention toward tracers, which
can detect the release (via DAT and VMAT) and activation (DRs) of
dopamine. The measures of SN uptake of [11C]DTBZ, a marker for vesicular monoamine transporter type 2 (VMAT2), and [11C]CFT, a
marker for dopamine active transporter (DAT), do correlate with nigral
cell counts throughout the full range of nigral cell loss (Tabbal et al.,
2012). These ﬁndings are consistent with a postmortem study of PD
that demonstrated a ﬂooring eﬀect of presynaptic dopaminergic measures in patients with moderate disease (Kordower et al., 2013) and in a
longitudinal PET study in people with PD (Kuramoto et al., 2013).
However, as we mentioned earlier, no tracers can accurately detect D2R
or D3R because of the high structural similarity between the two receptors.
2.2. Quantitative autoradiography assay for measuring D2R and D3R
densities
We developed a quantitative autoradiography based mathematical
model for calculating the absolute densities of D2R and D3R using in
vitro binding data obtained from D3R preferring antagonist [3H]WC-10
(Xu et al., 2009) and D2R preferring antagonist [3H]raclopride (Xu
et al., 2010). [3H]WC-10 and [3H]raclopride bind to D2R and D3R with
diﬀerent labeling proportions. The speciﬁc bound amount of receptors
of single concentration of [3H]WC-10 or [3H]raclopride binding can be
expressed by the formulas:
[3H]WC-10: a1D2 + b1D3 = B1;
[3H]raclopride: a2D2 + b2D3 = B2.
Where a1 and b1 are the fractional occupancies of [3H]WC-10 to D2R
and D3R; B1 is the apparent receptor binding density (D2+D3) directly
measured from autoradiography studies of [3H]WC-10; a2, b2, and B2
are the same parameters for [3H]raclopride; D2, D3 are the absolute
densities of D2R and D3R. The absolute densities of D2R and D3R were
calculated by solving the simultaneous equations:

D2 =

b2 B1 − b1B2
;
a1b2 − a2b1

D3 =

a1B2 − a2B1
a1b2 − a2b1

This novel assay has been used for evaluating DR subtypes alterations in mouse models of sleep deprivation and attention deﬁciency
(Brown et al., 2011; Lim et al., 2011), and genetic PD models including
DJ-1 and Pink-1 knockout (KO) rats (Sun et al., 2013b). The ﬁrst
3
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Fig. 1. Autoradiograms show the diﬀerential distribution
of D1R, D2R, D3R, DAT and VMAT2 in the striatal and
extrastriatal regions of human brain sections. [3H]
Microscale standards (ranging from 0 to 36.3 nCi/mg)
were also counted for the calibration of radioactivity). The
following CNS anatomical regions have been denoted:
Precommissural putamen (PrePu); Precommissural caudate (PreCd); Nucleus accumbens (NAc); Internal capsule
(IC). Globus pallidus external part (GPe); Globus pallidus
internal part (GPi); Postcommissural putamen (PostPu);
Postcommissural caudate (PosCd); Thalamus (Th);
Substantia nigra (SN); Red nucleus (RN). D3R density is
higher than D2R in Th, RN, SN and GPi. dopamine active
transporter (DAT); vesicular monoamine transporter 2
(VMAT2).

increases in inﬂammatory cells, and aggravates inﬂammatory response
(Ilani et al., 2004). This phenomenon may play a critical role in PD
pathogenesis as the CD4 + T-cells obtained from PD patients have
higher Th1-biased diﬀerentiation than those obtained from healthy
control, which lead to 2 fold higher frequency of Th1 cells in PD individuals than in healthy control (Elgueta et al., 2019). It has also been
observed that the T-cells with higher densities of D3R inﬁltrate through
the BBB and into the SN and induce the activation of microglia
(Gonzalez et al., 2013), resulting in the production of more inﬂammatory factors when compared with D3R-/- counterparts (Xue
et al., 2016). Activated microglia further induce neuroinﬂammation
and subsequent neurodegeneration of DAergic neurons in the SN - one
of the main pathological characteristics of PD (Elgueta et al., 2019).
One study of note, directly correlated the expression of D3R in peripheral blood correlated with neuroinﬂammation in the CNS, degeneration of DAergic neurons in SN, and the occurrence of PD. In this
instance, RAG1 KO mice - which lack T-cells - were resistant to MPTPinduced neurodegeneration. However, after these mice were reconstituted with wild-type CD4 + T-cells, they were susceptible to MPTPinduced DAergic neuronal damage. In contrast, RAG1 mice that were
administrated D3R−/− CD4 + T-cells were completely refractory to
neuroinﬂammation and consequent neurodegeneration (Gonzalez et al.,
2013).
Therefore, it was proposed that high expression of D3R mRNA in the
blood be considered as the disease speciﬁc biomarker during the preclinical stage of PD. A research observed the change of D3R mRNA
blood cells of MPTP-treated mice at the presymptomatic stage. The
results showed that D3R mRNA was enhanced in the mice at the presymptomatic PD stage, however decreased at the symptomatic PD stage
(Kim et al., 2018). All mice in the study eventually showed signiﬁcant
decrease of DA content in the striatum at the symptomatic stage (Kim
et al., 2018). Thus, Inhibition of D3R prior to the onset of clinical
conditions may hinder the pathogenesis of PD. One research showed
that before the administration of MPTP, which implies the pathogenesis
of PD, injection with D3R selective antagonist PG01037 or using D3R−/
−
mice could completely reverse neuroinﬂammation and consequent
neurodegeneration, thus eliminate parkinsonian symptoms (Elgueta
et al., 2017).
However, the evidence for a protective role of D3R inhibition in
mitigating PD pathogenesis is not completely consistent. There is a

comprehensive analysis of presynaptic (VMAT2 and DAT) and postsynaptic (DR) biomarkers in the striatal and extrastriatal regions was
conducted in aged human brains (Sun et al., 2012). The diﬀerential
distribution and reported density of D1R, D2R, D3R, DAT and VMAT2
are shown in Fig. 1 (Sun et al., 2012). D3R was upregulated, whereas
D1R and D2R were not, in striatum and downregulated in SN in PD
dementia brains. The observed increase in striatal D3R may reﬂect a
compensatory change upon dopaminergic denervation, while the reduction of nigral D3R density reﬂects neuronal loss in the nigrostriatal
system in PD with dementia (Sun et al., 2013a).
3. The change of D3R expression in preclinical or prodromal stage
of PD
Due to limitations in ligand selectivity, although several early studies used nonselective D2R/D3R ligands which indicated a potential
role of D2R in PD, the potential inﬂuence of D3R in PD pathogenesis
cannot be excluded. For example, studies using raclopride and fallypride demonstrated that D2R density increase in the striatum of earlystage PD patients (Fisher et al., 2013; Rinne et al., 1995). Another
study, using raclopride, showed that there was increased binding of
D2R/D3R in the early symptomatic stage of MPTP-intoxicated monkey
model (Ballanger et al., 2016). However, both raclopride and fallypride
do not diﬀerentiate between D2R and D3R (Le Foll et al., 2014b;
Mukherjee et al., 2015). One research also proved that it is the D3R,
rather than D2R mediated modulation was enhanced to induce Ca2+
current and synaptic GABA release in striatal neurons after DA depletion which mimics the early pathological feature of PD in an in vitro
study (Prieto et al., 2011).
Why D3R is increased in the early stage of PD? Increased D3R
promotes T-cell activation and induces neuroinﬂammation, which may
underlie the role D3R activation plays in PD pathogenesis. The activation of D3R on the surface of T-cells reduces cAMP levels and extracellular regulated protein kinases 2 (ERK2)-phosphorylation, increases proliferation and adhesion of T-cells, enhances CD4 + T-cell
activation(Franz et al., 2015), further attenuates T-helper 2 (Th2) differentiation, and promotes Th1 responses by regulating cytokine signaling 5, a negative regulator of Th2 development (Pacheco, 2017). The
activation of D3R produces changes in T cells that eventually leads to
their ability to cross the BBB, changes in their cytokine proﬁle,
4
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common notion that chronic tobacco use is associated with a lower risk
for PD. Researchers observed that nicotine induced D3R activation to
help signaling structural plasticity in mesencephalic DAergic neurons
(Collo et al., 2013). Moreover, another study proposed that this stimulation of D3R by nicotine induced D3R-nAChR heteromer activation
that attenuated α-syn aggregation (Bono et al., 2019). In addition,
others reported a signiﬁcant decrease of D3R mRNA expression in
peripheral blood lymphocytes (PBLs) of PD patients compared with
healthy controls (Gui et al., 2011). These studies suggests conﬂicting
conclusions; either a decreased density of D3R or the inactivation of
D3R is an indication of the early stage of PD.
There are many factors that may be inﬂuencing the inconsistent
results in this line of research. First, there is a possibility that a high
density of D3Rs may reﬂect a compensatory mechanism, common for
many receptors, due to the dopamine depletions or inactivation of D3R.
Thus, the increased D3R expression in early PD and the treatment of
diagnosed PD with D3R agonists are not contradictive. Second, it has
been suggested that although D3R densities are observed to change, it is
actually the ratio of D3R to related neuroreceptors that is associated
with the onset of PD. Animal model studies have shown that the continuous increase in the D1R/D3R ratio may be a physiological basis of
PD among middle-aged and elderly populations (Keeler et al., 2016).
Third, in recent years there has been a focus on the relationship between D3R polymorphism and PD pathogenesis. A study evaluating the
association between the polymorphisms of D2R and D3R genes (D2R:
rs1800497, rs1079597, rs6278, rs6279, rs273482, rs1799732 and
rs1076563; D3R: rs6280 and rs2134655) and their inﬂuence in PD
pathogenesis was conducted among 4279 PD cases and 5661 controls.
The results showed a signiﬁcant association between PD occurrence and
D3R rs2134655 polymorphism (Dai et al., 2014). Another study discussing the relationship between D3R polymorphisms and the age of PD
occurrence showed that D3R polymorphism (rs6280), rather than D2R
(Taq 1A, rs1800497), correlated with younger PD onset with a 4.4-year
decrease in mean age of onset (Hassan et al., 2016). These observations
lead us to believe that in order to determine whether D3R density
changes contribute to the development of PD, we need to take diﬀerent
genotypes of D3R into consideration.
In other words, there is no clear indication that D3R expression can
be used as a diagnostic marker for early onset of PD. Although most
studies mentioned above suggested the possibility, further studies are
needed to clarify the role D3R plays in PD prediction. Further studies
should clarify whether changes in D3R appear because of the pathological changes of PD or D3R changes induce PD pathogenesis.
Furthermore, the degree to which one D3R mutation or various genotypes inﬂuence PD pathogenesis is of importance for further research. It
should be noted, there is debate about evidence of changes in D3R
being used as signs of preclinical or prodromal PD. However, we hope
that in-depth research can help people ﬁnd an early stage marker of PD
as soon as possible.

decreased expression of D3R may be reversed by long term L-DOPA
treatment (Bezard et al., 2003), or other D1R agonist therapies
(Morissette et al., 1998).
Furthermore, although D3R may lead to the decrease of DA in the
synaptic cleft due to its role as autoreceptor in the presynaptic membrane; it should be mentioned that the formation of D1R-D3R heteromers which appears mostly postsynaptically(Marcellino et al., 2008)
leads to postsynaptic signaling similar to D1R activation. A function
signiﬁcantly diﬀerent than D3R’s role as autoreceptor (Schmauss,
2000). D3R stimulation potentiated signiﬁcant D1R mediated locomotor activation in reserpinized mice PD models (Marcellino et al.,
2008), likely due to the fact that there is only weak coupling between
the D3R promoter and Gi/o in D1R-D3R heteromer. Instead, D3R enhances D1R signaling over the Gs/olf complex, through allosteric receptor-receptor interactions (Fuxe et al., 2015). Therefore, this does not
exclude the possibility that increased D3R could be a diagnostic criterion for early onset of PD as we mentioned earlier in this review.
Despite inconsistencies that exist, we believe the activities of D3R
are reduced in all these studies. Only D3R agonists are routinely used in
preclinical and clinical interventions of PD; PD research studies seldom
mention D3R antagonists.

4. Involvement of D3R in PD treatment

5. Possible mechanism involving in D3R activation

4.1. Change of D3R in PD development

5.1. D3R activation inhibits DA reuptake and breakdown in synaptic
terminals

4.2. D3R agonists in alleviating PD symptoms
Therefore, D3R agonists attract more and more attention in the
treatment of PD in in vivo and in vitro models.
In animal studies, D3R agonists alleviated DA depletion in the
striatum, attenuated DAergic neuron cell death in the SN, ameliorated
microglial activation, and improved behavioral performance in
Parkinsonism mice. These eﬀects appear to be D3R dependent as they
did not appear in D3R KO mice or in mice that received D3R antagonist
pretreatment (Lao et al., 2013; Li et al., 2010a).
In clinical research trials, the eﬃcacy of D3R preferential agonist,
rotigotine, has been demonstrated in a series of phase III clinical studies
with good tolerability and safety. Studies included patients with early
and advanced stages of PD and established a dose-response relationship
between escalating doses of rotigotine and improvements in PD symptoms (Benitez et al., 2014; Elmer et al., 2012; LeWitt et al., 2007; Pham
and Nogid, 2008). Pramipexole, a D3R preferring agonist with a higher
receptor selectivity, is eﬀective as a monotherapy in early stage PD and
able to delay the occurrence of dyskinesia in participants that fail to
respond well to L-DOPA treatment(Antonini et al., 2010). Pramipexole
can also be used as an adjunctive therapy in advanced PD (Antonini
et al., 2010; Schapira et al., 2011) and should be established as a
treatment option for all stages of PD patients (Frampton, 2014).
However, the principal for D3R agonists in PD treatment is still
obscure, and we will discuss the potential mechanisms in detail in the
following part.

Similar to the role of D3R in predicting PD occurrence, the changes
of D3R in the SN and striatum during PD development are conﬂicting.
Some studies have shown reduced D3R expression within the striatum
in parkinsonism rats (Favier et al., 2017), monkeys (Morissette et al.,
1998), and drug-naïve PD patients (Boileau et al., 2009). However,
other studies indicated that D3R or mRNA expression was up-regulated
in Parkinsonism rats (Sun et al., 2013b) and cats (Wade et al., 2001).
The controversies involving D3R expression in PD models and patients may be related to the time course of PD. One study indicated that
D3R mRNA increased six-fold by 2 weeks and then decreased in baboons after MPTP administration (Todd et al., 1996). Medication may
also alter the expression of D3R protein. Researchers believe that

D3Rs are located both postsynaptically and presynaptically on DA
target cells on DAergic neurons, respectively. Thus D3R works as an
autoreceptor and generally provides an important negative feedback
mechanism for neurotransmitter release that works in response to
changes in extracellular neurotransmitter levels (Beaulieu and
Gainetdinov, 2011). Therefore, it is believed that increased sensitivity
or activation of D3R results in decreased DA content (Bustos et al.,
2004). However, in certain circumstances, the activation of D3R might
inhibit two main processes of DA metabolism including DA reuptake
and breakdown, which may underlie the possible mechanisms by which
D3R agonists alleviate PD symptoms.
5

Ageing Research Reviews 57 (2020) 100994

P. Yang, et al.

patients (Luo et al., 2016), measured by western blot or serum exosomes analysis.

5.1.1. D3R stimulation inhibits DA reuptake
The released DA in the synaptic space can be removed within milliseconds via DA reuptake through DAT. DAT pumps DA back into the
cell to avoid persistent DA-induced biological eﬀects. The transported
DA can be encapsulated in vesicles for recycle by VMAT2. If eﬀect of
VMAT2 is hindered, there is a blockade of DA reuse and causes PD.
D3R activation reduces the aﬃnity of DA for DAT and hinders DAT
activity to induce persistence of DA biological eﬀects. CastroHernandez et al. found that a physical interaction between D3R and
DAT reduced DA aﬃnity for DAT in the absence of any changes in DAT
density and subcellular distribution, and led to a decrease in DA uptake.
This modulatory eﬀect was D3R but not D2R dependent as the protective eﬀect of pramipexole was absent in D3R−/− mice, but present in
D2R−/− mice (Castro-Hernandez et al., 2015). Another demonstrated
that D3R mediated long-term deﬁcits in DAT function, and D3R inactivation attenuated methamphetamine-induced decreases in striatal
DAT (Baladi et al., 2014). The direct modulation of DAT expression by
D3R agonists was also examined. Pramipexole was able to reduced DAT
immunoreactivity and lowered the Vmax for DA uptake into striatal
synaptosomes in WT type mice, while this eﬀect was not observed in
D3R KO mice (Joyce et al., 2004). It is an interesting observation that
the blocking of DAT may further activate D3R (Swant and Wagner,
2006), thus forming a positive feedback loop to block DAT.
D3R has also shown a close relationship with VMAT2. The D3R
preferring agonist, quinpirole, can increase vesicular DA uptake in
puriﬁed rat striatal vesicles; this eﬀect was associated with redistribution of VMAT2 within nerve terminals (Truong et al., 2004). Pramipexole was also proved to be able to rapidly increase vesicular DA
uptake in synaptic vesicles prepared from striatum of treated rats and
this eﬀect is associated with a redistribution of VMAT2 immunoreactivity within nerve terminals (Truong et al., 2003).

5.2.2. D3R activation inhibits α-Syn aggregation
D3R activation also inhibits the aggregation of α-Syn. When co-incubated with an α-Syn solution, ropinirole inhibited α-Syn oligomer
formation in an in vitro study (Ono et al., 2013). A study showed that αSyn aggregate inclusions distributed both in mesencephalic DAergic
neuron cell bodies and dendrites were dramatically reduced by quinpirole. This eﬀect was signiﬁcantly antagonized by the D2R/D3R antagonist sulpiride (Bono et al., 2018). A recent study published by the
same group showed that nicotine could inhibit the accumulation of αSyn though a D3R-nAChR heteromer. This eﬀect was disrupted by D3RnAChR heteromer speciﬁc interfering TAT-peptides (Bono et al., 2019).
Another study proved that the co-incubation of D-520, a newly developed D3R selective agonist with Ki(D2R)/Ki(D3R) = 119, inhibited αSyn aggregation, reduced the toxicity of α-Syn when compared to
control group (Modi et al., 2014). It is worth mentioning that some
researchers believe that phosphorylated α-Syn accounts for 90 % of αSyn aggregates in Lewy bodies(Karampetsou et al., 2017), while pramipexole inhibited α-Syn phosphorylation to alleviate the formation of
this neurotoxic aggregation (Chau et al., 2013).
5.2.3. D3R activation promotes α-Syn clearance through autophagy
The scavenging eﬀect of D3R agonists on α-Syn may depend on
autophagy (Fig. 3). Autophagy helps remove abnormally aggregated
proteins via lysosomal degradation, and its dysfunction is involved in
the occurrence of PD.
One in vitro study demonstrated that co-incubation of rotenone
treated PC12 cells with pramipexole led to a promoted clearance of αSyn secondary to the up-regulation of Beclin1 (BECN1), an autophagyassociated protein. This eﬀect was DR dependent because the R(+)
enantiomer of pramipexole, which is devoid of agonist activity, showed
no similar eﬀect on autophagic markers or autophagosome formation
(Wang et al., 2015a). And we believe that D3R may play an more important role than D2R as that D3R blockade seemed to be more eﬀective
than D2R blockade in suppressing the expression of autophagy related
proteins, such as microtubule-associated protein 1 light chain 3(LC3)-II
and BECN1 (Wang et al., 2015a). Similar results were also observed in
an animal study which showed a massive aggregation of autophagosomes/autophagic vacuoles when using pramipexole (Li et al., 2010b).

5.1.2. D3R stimulation inhibits DA breakdown
Although we cannot provide a direct example of interactions between D3R and DA metabolic enzymes, apomorphine, a D3R preferring
agonist (D3R aﬃnity 2–4 fold greater than for D2R) acts as a reversible
competitive inhibitor of monoamine oxidase (MAO) A and B with IC50
values of 93 and 214 μM, respectively (Youdim et al., 1999).
While there is considerable evidence that D3R activation may regulate its transport and inhibit its metabolism (Fig. 2), some studies do
not support this conclusion. For example, some believe D3R antagonists
promote the release of DA from mesolimbic DAergic neurons (Rivet
et al., 1994), some believe that the protective eﬀect of D3R agonists is
independent of changes in DA concentration (Svensson et al., 1994).
These views have some merits; in both PD patients and in animal
models of PD, damage to the nigrostriatal pathway might result in a
majority of the indicators below normal levels, making it easy to observe changes in protein expression and DA levels in these cases. Additionally, those changes in protein expression and dopamine level may
be due to the overall therapeutic eﬀect of D3R agonists.
These conﬂicting observations provide novel insights into the longterm antiparkinsonian actions of D3R agonists. From all these results,
we believe that D3R agonists can be regarded as regulators of DA
ﬂuctuation, and might thus contribute to the treatment of PD.

5.3. D3R activation enhances secretion of BDNF
Brain derived neurotrophic factor (BDNF) plays an important role in
processing chemical communication, facilitating the survival and maturation of DAergic neurons and enhancing functional re-innervation in
the adult brain striatum. Degeneration of DAergic neurons is found in
the absence of BDNF while enhanced levels of BDNF may improve
symptoms in PD patients (Jiang et al., 2019).
In an in vitro experiment, researchers found that pramipexole rescued TH + and Microtubule-Associated Protein(MAP)+ neurons injury, and this protective eﬀect was dependent on the release of BDNF
(Imamura et al., 2008). Another study demonstrated that when primary
mesencephalic cultures were co-incubated with conditioned medium
from pramipexole or ropinirole treated primary cultures, the number of
DAergic neurons was signiﬁcantly increased. This protective eﬀect
could be blocked or diminished by BDNF neutralizing antibodies or by
D3R antagonists, but not by D2R antagonists (Du et al., 2005). Other
groups have reported similar ﬁndings. The protective eﬀect of D3R
activation disappeared when neurons were antagonized by selective
D3R antagonists, or by immuno-neutralization of BDNF. Besides, the
protective eﬀect is D3R and BDNF dependent, but not D1R and D2R
dependent (Collo et al., 2018; Presgraves et al., 2004).
Moreover, not only does D3R modulate expression of BNDF, but also
BDNF inﬂuences the normal expression of D3R in neurons (Guillin

5.2. D3R activation decreases α-Syn accumulation
The protein α-Syn is detrimental to DAergic neurons in the SN, and
may result in the formation of Lewy bodies and subsequent cell death.
Many studies suggested that D3R agonists may exert neuroprotective
eﬀect through modulating abnormal aggregates of α-Syn (Fig. 3).
5.2.1. D3R activation decreases α-Syn expression
D3R activation is believed to inhibit α-Syn expression in animal
models and PD patients. Pramipexole was proved to be able to decrease
α-Syn expression in a mouse PD model (Zhang et al., 2017) and in PD
6
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Fig. 2. Eﬀects of presynaptic D3R activation in modulating
D3R content. D3R promotes the function of VMAT2 to boost
the release of DA, hinders DAT to restrain the reuptake of DA,
and inhibits MAO to reduce the breakdown of DA, eventually
augments the content of DA in the synaptic cleft. dopamine
active transporter (DAT); vesicular monoamine transporter 2
(VMAT2); monoamine oxidase (MAO).

5.4. D3R activation ameliorates neuroinﬂammation

et al., 2001). BDNF increases striatal level of D3R via tyrosine kinase
receptor B (TrkB), thereby activate the relevant pathways (Jeanblanc
et al., 2006). Saylor et al. found that young BDNF+/− mice expressed
lower levels of D3R mRNA than wild type mice, while a single microinjection of BDNF restored the expression of D3R. This suggests that
both D3R and BDNF play a synergistic role in protecting striatal neurons (Saylor and McGinty, 2010).

Neuroinﬂammation is a double-edged sword. Inﬂammation plays an
important defensive role in maintaining CNS homeostasis. However,
uncontrolled neuroinﬂammation can disrupt blood-brain barrier (BBB)
patency and may continuously trigger neuronal cell death. Obvious
symptoms of enhanced neuroinﬂammation have been observed in post
mortem brains of PD cases while non-steroidal anti-inﬂammatory drugs
(NSAIDs) have been proposed to play a protective role in PD patients
Fig. 3. D3R activation inhibits abnormal aggregation and
enhances clearance of α-Syn. D3R activation hinders the
phosphorylation of α-Syn to inhibit the abnormal formation of ﬁbrils. Besides, D3R activation also enhances autophagy-dependent degradation of toxic ﬁbrils by modulating autophagy related protein LC3 and Beclin1. αSynuclein (α-Syn); microtubule-associated protein 1 light
chain 3 (LC3).
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antioxidant and D3R activating engagements of D3R agonists play critical roles in its neuroprotective actions in PD treatment (Ling et al.,
1999).

(Vivekanantham et al., 2015; Wahner et al., 2007).
It was observed that pramipexole treatment signiﬁcantly alleviated
microglial activation, attenuated DAergic neuron loss in SN and improved rotarod performance in an animal study (Li et al., 2010b). Other
studies demonstrated that pramipexole could block the secretion of
inﬂammatory factors, alleviate nerve inﬂammation and inhibit astrocytes activation (Kang et al., 2016; Lieberknecht et al., 2017).
The anti-inﬂammatory eﬀect observed above is D3R dependent. A
novel D3R preferring agonist D264 was shown to exert a protective
eﬀect in two mouse models of PD. Pretreatment with D264 seven days
before MPTP or lactacystin administration dramatically improved behavioral performance, attenuated neuron loss through ameliorating
microglial activation and increasing BDNF levels; these protective effects could be blocked by administering a D3R antagonist U99194 (Li
et al., 2010a).
Contradictory evidence has also been presented. Although continuous pramipexole administration produced signiﬁcant preservation
of TH + cells degeneration and alleviated TH + terminals loss in parkinsonism rats who received stereotaxic injection of lipopolysaccharide
(LPS) into SN, there was no eﬀect on the expression of inﬂammatory
markers; the authors believed that the protective eﬀect of pramipexole
could be due to enhanced tolerance to inﬂammation (Iravani et al.,
2008).
We have proposed that D3R activation might enhance inﬂammation
in the early stage of PD pathogenesis. So what leads to conﬂicting
evidence? We think that is partly due to the complicated role of D3R in
modulating inﬂammation. A study has shown that when Chinese
hamster ovary cell (CHO) cells which overexpress D3R were activated
by low concentration of DA, the release of arachidonic acid (AA) was
inhibited, while high concentration of DA increased the release of AA.
This suggested that excessive activation of D3R might be associated
with inﬂammation, while moderate activation might play an anti-inﬂammatory role (Nilsson et al., 1999).

5.6. D3R activation promotes neurogenesis
PD demonstrates obvious impaired neurogenesis. A hallmark of PD
is the loss of TH + neurons in the SNpc and the reduction of DAergic
projections to the striatum, therefore increasing neurogenesis helps
alleviate the symptoms of PD (Salvi et al., 2016). Although it was once
believed that adult neurogenesis occurs only in the hippocampal dentate gyrus (DG) and subventricular zone (SVZ) regions, recent studies
have shown that newly generated neurons may also occur in areas
previously considered as non-neurogenic, e.g., the striatum (Salvi et al.,
2016).
There is close relationship between D3R and neurogenesis. The
expression of D3R in the CNS occurs in the very early stages of development, and mainly exists in the site of neurogenesis (Van Kampen and
Robertson, 2005). It was observed that in hiPSC-derived DAergic neurons, treatment with D3R preferring agonists such as quinpirole and
ropinirole promoted the reproduction of neuronal progenitor cells
(Bono et al., 2018). In one study, the results showed that there was
signiﬁcantly increased proliferation of neurons in the DG and doublecortin (DCX)+ neuroblasts in the striatum of pramipexole treated
mice (Salvi et al., 2016). Other studies showed that the maximal dendrite length, number of primary dendrites, number of DAergic neurons
and [3H]dopamine uptake of TH + neurons were signiﬁcantly enhanced when treated with quinpirole and D3R agonist 7-OH-DPAT,
while the neurotrophic eﬀects were all eliminated when D3R was
blocked (Collo et al., 2008; Van Kampen and Eckman, 2006). Another
study in lesioned zebra ﬁnches showed that 7-OH-DPAT led to signiﬁcant reduction of lesion size and increased numbers of migrating
neuroblasts and newborn cells in the striatal vocal nucleus area X, while
the same eﬀect was not seen in D3R antagonist U99194 treated cohorts
(Lukacova et al., 2016).
The studies above suggested that the increased neuronal production
eﬀect was conducted via a direct eﬀect on D3R. In addition, rat experiments showed that D3R activation could signiﬁcantly increase
neurogenesis in SVZ and SNpc (Van Kampen and Robertson, 2005),
which are also the most vulnerable regions in PD. Pramipexole signiﬁcantly promoted neurogenesis in the SVZ area of adult mice or rats,
manifested by enhanced neuron number, neuronal diﬀerentiation, Sphase population at cell cycle and incorporation of BrdU, which could
all be blocked by D3R antagonist U99194A. Pramipexole also increased
the number of GFAP-positive cells and enhanced the expression of
neuronal markers DCX and MAP2, and resulted in enhanced motor
activity (Merlo et al., 2011; Winner et al., 2009).

5.5. D3R activation alleviates oxidative stress injury
Oxidative stress is believed to be involved in PD. Increased lipid
peroxidation and impaired mitochondrial function are found in the SN
of PD patients. In numerous experimental models, exogenous toxins
such as MPTP produce free radicals which induce PD (Zou et al., 2000).
Rotigotine induced neuroprotective eﬀect against glutamate toxicity in
primary dopaminergic cultures through signiﬁcantly decreasing the
production of free radicals via dopamine receptor stimulation (presumably via the D3R) (Oster et al., 2014). Thus, it is possible that D3R
activation may inﬂuence PD progression through its antioxidant eﬀect.
D3R activation was shown to inhibit reactive oxygen species (ROS)
generation in neurons or animals. Pramipexole inhibited the production
of mitochondrial ROS and prevented cell death, when compared with
SH-SY5Y cells treating with H2O2 (Ferrari-Toninelli et al., 2010). Rotigotine signiﬁcantly alleviated rotenone-induced primary mesencephalic neuronal death due to the signiﬁcant attenuation of ROS production (Radad et al., 2014). An in vivo study showed that treating mice
with MPTP increased lipid peroxidation products and loss of TH + DA
neurons in SN, while pramipexole treatment inhibited lipid peroxidation and protected SN injury (Zou et al., 2000).
The reason may be that D3R activation increases the level of enzymes which reduce ROS. Pramipexole was shown to normalize the
level of Glutathione (GSH) and GSH peroxidase (Lieberknecht et al.,
2017) in animal models of PD. Ropinirole is believed to increase the
activities of GSH, catalase, and Superoxide dismutase which scavenge
ROS, while pretreatment with D2R/D3R antagonist blockers abolished
this protective eﬀect (Iida et al., 1999).
Although most authors believed that D3R activation is necessary for
the demonstrated reduction in ROS injury (Li et al., 2010a), some have
shown that this can be independent of D3R activation (Le et al., 2000).
Although more research is needed to clarify this issue, both the

5.7. D3R synergistically promote biological eﬀect of D1R stimulation
Most DR agonists are for the D1R and D2R families, or the D2R
family. The use of D1-selective/preferring agonists in PD therapeutics is
an ongoing area of research. However, among all of these DRs, D1R is
the most abundantly expressed receptor in the striatum (Perachon
et al., 1999) and is believed to play a critical role in PD pathogenesis
and treatment. Clinically, dopamine agonists with the highest D1R afﬁnity have an eﬃcacy most similar to L-DOPA, although not as eﬀective. The full activation of D1R is the key to directly alleviate PD related
symptoms (Lewis et al., 2006). Increased D1R expression is considered
one of the critical elements for establishing a given dopamine agonists’
clinical sensitivity to reduce PD symptoms (Hisahara and Shimohama,
2011). Deﬁciencies in D1R expression have led to Parkinsonian motor
symptoms in animal studies (Centonze et al., 2003). It could be a logical
conclusion that the synergistic eﬀect between D3R and D1R may also
participate in the alleviating eﬀect of D3R agonists in PD.
The interaction between GPCRs may interfere with the GPCR
8
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caudate D3R expression after nigrostriatal degeneration was reversed
after L-DOPA treatment (Quik et al., 2000). Changes were not limited to
the expression of D3R but also the binding to exogenous ligands was
shown to have been enhanced in the striatum of rats following repeated
administration of L-DOPA (Bordet et al., 1997). Furthermore, the differences of D3R among species should also be taken into consideration.
There is more widely distributed D3R in the striatum in humans and
primates than in rats (Silverdale et al., 2004), a diﬀerence that may
yield contradictory results when sorting out the eﬀects of D3R agonists/
antagonists. Three, the hypothesis that the inhibition of D3R alleviates
PD symptoms has also been challenged due to the poor selectivity of
some of the aforementioned D3R antagonists. Nafadotride, for example,
is believed to be a D3R blocker but also binds with the 5-HT receptor
(Audinot et al., 1998) and only shows 6.2 fold selectivity for D3R over
D2R (Audinot et al., 1998). Another study used homozygous (D3-/-),
heterozygous (D3+/-) mutant and wild-type (D3+/+) mice to analyze
the eﬀect of D3R agonists and antagonist in locomotor activity. Results
of this study concluded that all D3R agonists decreased locomotion to a
similar extent in all three genotypes while D3 receptor antagonist increased locomotor activity. However, there were no apparent diﬀerence
between the D3-/-, D3+/-, and D3+/+ genotypes (Boulay et al., 1999).
This research illustrates the possibility that there might be other alternative adaptive mechanisms involving still other receptors. Four,
there is basis for reinterpreting some of the opposing results. In the
instance where authors believe that D3R agonist weaken the anti-Parkinson eﬀects of L-DOPA, it was concluded that D3R stimulation aggravated parkinsonian symptoms. However, it is reasonable to conclude
that the partial D3R antagonist, BP897, could antagonize the antiParkinson eﬀect of L-DOPA, whose metabolites are considered a complete agonist. After the dose of L-DOPA was increased, the inhibitory
eﬀect of BP897 on the therapeutic eﬀect of L-DOPA disappeared(Hsu
et al., 2004), this supports our deduction and is a common phenomenon
when discussing the eﬀect of partial agonists. In addition, the above
results also conﬁrm that the dosage of L-DOPA may aﬀect our judgment
relative to the role of D3R in PD. Lastly, other authors believed that
among various methods used to evaluate motor ability in diﬀerent
species of animals may lead to diﬀerences in the evaluation of the PD
improvement eﬀect in question (Hsu et al., 2004).

signaling in both quantitative (ligand aﬃnity) and qualitative (downstream pathway disruption) ways. It was proved that the interaction of
D3R on D1R increases the aﬃnity of D1R with its ligand, but has little
eﬀect on the aﬃnity of D3R with its ligand (Marcellino et al., 2008). For
example, selective D3R agonist PD128907 reduced the ED50 for the
D1R agonist SKF 38393 from 56 to 4 nM in certain circumstances
(Avalos-Fuentes et al., 2013). Once the aﬃnity of DA to D1R is increased, G-protein signaling and cAMP accumulation is enhanced
(Leggio et al., 2016). Deleting or pharmacologically blocking D3R attenuated important molecular markers in the D1R-neurons such as FBJ
murine osteosarcoma viral oncogene homolog B(FosB), ERK, and histone-3 (H3)-activation (Solis et al., 2017), while activating D3R in the
SN enhanced D1Rs to induce γ-aminobutyric acid (GABA) release in SN
(Avalos-Fuentes et al., 2013) and striatum (Cruz-Trujillo et al., 2013).
All these directly showed how D3R might enhance the physiological
function of D1R neurons by activating D1R.
In one study, using risepinized mice in which DA was exhausted,
locomotor activity was enhanced by the administration of D1R agonist.
The eﬀect of D1R agonist was potentiated through co-administration
with the D3R agonist PD128907 dose-dependently. Furthermore, in
light of the contested D3R selection properties of PD128907, D3R KO
mice were also used. It was shown that although D1R agonist signiﬁcantly enhanced the motor activation in both WT and D3R KO mice
by itself, PD128907 signiﬁcantly potentiated the locomotor activity
induced by D1R stimulation in WT mice. However, similar results were
not obtained with D3R KO mice (Marcellino et al., 2008). These results
suggest that it is the activation of D3R which plays a critical synergistic
role in promoting the D1R mediated behavioral eﬀect.
5.8. Diﬀerent voices
Although we have mentioned much evidence asserting the critical
role that D3R may play in alleviating PD symptoms via diﬀering mechanisms, studies have shown conclusions which are at odds with ours.
Some studies conclude that D3R stimulation may be the source of debilitating PD symptoms. One study found that when S33084 - a selective D3R antagonist - was administered alone, Parkinsonian disability
was alleviated in 6-OHDA injured rats (Mela et al., 2010) and a low
dose of S33084 potentiated the anti-Parkinsonian eﬀect of both L-DOPA
and ropinirole (Silverdale et al., 2004). Nafadotride, another D3R antagonist, was reported to enhance locomotor activity at low doses in
rats (Sautel et al., 1995). It was also reported that BP897, a D3R agonist, weakened the anti-Parkinson eﬀect of L-DOPA (Hsu et al., 2004).
When looked at on the whole, the conﬂicting nature of these reports
lead us to believe that the role of D3R in the treatment of PD needs to be
further discussed. We believe that in-depth discussion of these contradictions can help the research community better understand the role of
D3R in PD. We can think of several reasons for the conﬂicting evidence
present across the various studies. One, the therapeutic eﬀects of D3R
antagonists on PD may vary with the dosage. Although the mechanisms
of D3R antagonists are still unknown. Some reports indicate that low
doses of preferential D3R antagonist, S33138, was shown to potentiate
the antiparkinson action of ropinirole. However, the beneﬁts of this
drug diminished at a high dose (Millan et al., 2008). Another D3R
antagonist, nafadotride, similarly enhanced locomotor activity at a low
dose, while this locomotor activation was not observed at a high dose or
in some instance even decreased (Sautel et al., 1995). Still another
study has shown that high doses of D3R antagonists produce an increase
in disability, while low doses do not give such eﬀects (Hadj Tahar et al.,
1999). Two, the diﬀerence in D3R expression and binding state with its
ligand should also be taken into consideration. Contrary results may be
produced relative to diﬀering states of stimulation or inhibition of D3R.
Discrepancies may arise from changes relative to PD stage, treatment,
or between species. For example, in one report that utilized MPTP-lesioned baboons, expression of D3R increased for two weeks to a peak of
six fold before starting to decrease (Todd et al., 1996). The decline in

6. The role of D3R in PD associated non-motor symptoms
It is believed that D3R distributes abundantly in mesolimbic areas:
nucleus accumbens, olfactory tubercle, amygdala, islands of Calleja,
and in the striatum (Gurevich and Joyce, 1999; Jaber et al., 1996).
Thus, activation or inhibition of D3R may be associated with the
emotional, behavioral, motivational, and memory ﬂuctuations which
are commonly seen in PD patients. Common symptoms of these states
include depression, anxiety, psychosis and cognitive defects.
6.1. Sensory and mood deﬁcits
6.1.1. Depression
A reduction of the mesolimbic pathway precipitates the loss of
motivation and anhedonia - symptoms of depression (Leggio et al.,
2013). There is evidence that the down-regulation of expression and
function of D3R at the mesencephalon exists in major depression
(Leggio et al., 2013). The deﬁciency of D3R has also be posited to
contribute to increased incidence of depressive symptoms (MoragaAmaro et al., 2014), while D3R agonists are reported to exhibit antidepressant eﬀects in a rat model(Rogoz et al., 2004).
Studies have reported that commonly used antidepressants could
increase the expression, binding, or responsiveness of D3R in relevant
brain areas such as the islands of Calleja and the nucleus accumbens major projection areas of the mensolimbic dopaminergic system
(Lammers et al., 2000; Maj et al., 1998). Therapeutic eﬀects may depend on D3R as the preferential D3R agonist, cariprazine, exerted
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antidepressant eﬀects in WT mice. However, this eﬀect did not exist in
D3R KO mice (Duric et al., 2017). Thus suggesting that activation of
D3R be considered a potential method for the treatment of depression
in PD rats model (Carnicella et al., 2014). Common clinically used D3R
agonists, ropinirole and pramipexole, are reported to alleviate depressive symptoms in rats and PD patients further lending support to this
hypothesis (Antonini et al., 2010; Mavrikaki et al., 2014).

demonstrated in one human study by the fact that Gly/Gly individuals
had the lowest PPI while Ser/Ser individuals had the highest PPI
(Roussos et al., 2008). Despite the controversies surrounding the mechanisms underlying psychosis-like symptoms, much consideration to
this side eﬀect is needed when using DR agonists. Best clinical practices,
such as the reduction of doses or introducing antipsychotic medications
if necessary, should be followed.

6.1.2. Anxiety
D3R also plays an important role in anxiety. Results indicate that
D3R KO mice show anxiety-like symptoms. Evidenced by thigmotaxis in
openﬁeld tests, a signiﬁcant lower time spent in the lit compartment in
the light-dark box test (Moraga-Amaro et al., 2014). 7-OH-DPAT and
cariprazine, both are preferential D3R agonists, were found to exert
anxiolytic-like eﬀect in rats and mice models (Duric et al., 2017; Rogoz
et al., 2004). Cariprazine was also believe to alleviate anxiety/depression vs placebo in clinical application (Marder et al., 2019). One
clinically used anti-PD compound, ropinirole was proved to produce
anxiolytic-like eﬀects in the mouse, rat, and marmoset models (Rogers
et al., 2000). Another in vivo study suggested that activation of D3R be
considered a potential method of treatment for anxiety and depression
in PD rat models when compared with D1R and D2R activation
(Carnicella et al., 2014).

6.2. Dementia
The striatum is not only critically important in motor functions, but
also plays important role in cognitive functions. D3R receptors are
proved to speciﬁcally participate in cognitive aspects of striatal functions (Morissette et al., 1998).
D3R expression was shown to be severely reduced in AD patients
(Kumar and Patel, 2007). Having PD with an additional diagnosis of
dementia correlated with lower D3 receptor density. Correspondingly,
non-demented PD cases have elevated levels of D3R binding (Joyce
et al., 2001).
When pramipexole was used to treat mild-moderate AD individuals,
13/16 patients showed improved cognition (Bennett et al., 2016). Another report in bipolar disorder also conﬁrmed the therapeutic eﬀect of
pramipexole in cognitive impairment (Aprahamian et al., 2013).
However, the reasons are still obscure.
Some rat experiments showed that D3R activation could signiﬁcantly increase neurogenesis in SVZ and striatum (Van Kampen and
Robertson, 2005), the vulnerable regions in PD. That may partially
explain why treating with pramipexole could restore the synaptic
transmission and Long-Term Potentiation (Castro-Hernandez et al.,
2017).
However, there are also studies which do not support the view that
D3R activation promotes cognitive function (Chang et al., 2018; Sun
et al., 2013a). Whether activation of D3R may alleviate dementia in PD
needs validation through large-scale clinical trials.

6.1.3. Psychosis
Psychosis is a common neuropsychiatric symptom of PD (Bleickardt
et al., 2012). Treatment with dopaminergic medication can also induce
psychosis. DR agonists are more likely to induce psychoses than LDOPA(Bleickardt et al., 2012) - making DR agonist therapy a critical
risk factor for PD psychosis (Han et al., 2018). The eﬀect of dopamine
agonists on psychosis may be closely related to prepulse inhibition
(PPI). PPI is a neurological phenomenon deﬁned by the reduction in
startle magnitude following a weak prepulse (or prestimulus) and is
used for the measurement of sensorimotor gating (Weber et al., 2009).
PPI reduction (or deﬁcit) is detected in schizophrenia patients and is
among the most consistent and robust markers for this disorder
(Swerdlow et al., 2006).
Many studies have shown that PPI is related to 5-HT and NMDA
receptors, while D3R has been given more attention recently.
Apomorphine (Yang et al., 2017), ropinirole(Giakoumaki et al., 2007),
quinpirole (Nespor and Tizabi, 2008), and pramipexole (Chang et al.,
2010) were all believed to induce a signiﬁcant PPI reduction or deﬁcit
in animal models or human studies. It is thought that this eﬀect of PPI
reduction may be mediated by D3R agonism. Selective D3R antagonist,
Y-QA31, was shown to reverse PPI perturbation in methamphetamine
induce schizophrenia models (Sun et al., 2016). A D3R active drug, (S)pramipexole, decreased PPI when infused into the NAc and islands of
Calleja, in a dose-dependent manner. While (R)-pramipexole, a D3Rinactive molecule, had no eﬀect. Moreover, the PPI disruptive eﬀect of
pramipexole were prevented by D3R-selective antagonist (Chang et al.,
2012). Buspirone was also found to counteract the disruption of PPI
induced by MK801 in WT mice, subsequently exerting an antipsychoticlike eﬀect. This eﬀect may be mainly driven by antagonist activity at
D3Rs as the counteracting eﬀect disappeared in D3R−/− mice (Torrisi
et al., 2017).
These observations indicate that the PPI disruption seen with DR
agonists may be mediated by D3R, however the role of other DRs
cannot be ruled out (Varty and Higgins, 1998). Alternative explanations
posit that D1R (Ralph-Williams et al., 2003) or D2R (Ralph et al., 1999)
are essential for the disruption of PPI but not D3R (Ralph et al., 1999).
This may be due to the various mechanisms in which DR agonists induce psychosis. For example, it was reported D2R antagonists inhibited
apomorphine but not pramipexole induced PPI deﬁcit, while D3R antagonists inhibited pramipexole but not apomorphine induced PPI
deﬁcit (Weber et al., 2008, 2009; Zhang et al., 2007). Furthermore, D3R
Ser9Gly polymorphism may also inﬂuence their eﬀect on PPI,

6.3. Impulse control disorders
ICDs (such as, but not limited to, gambling disorders, hypersexuality, and compulsive eating and shopping) have been reported in PD.
ICD incidences are especially pronounced in PD patient populations
who have received DA replacement therapies (Voon and Fox, 2007),
and as such DR agonists are considered a major risk factor for ICD
(Marvanova, 2016). ICDs were more frequent in patients taking agonists than a L-DOPA monotherapy (Fasano and Petrovic, 2010), while
the D3-acting eﬀect was statistically associated with ICD development
(Fasano and Petrovic, 2010; Moore et al., 2014). Incidences of ICD are
also associated with the use of L-DOPA, and the combination of L-DOPA
and dopamine receptor agonists showed higher incidence of ICD than
dopamine receptor agonists alone(Weintraub et al., 2010). The reason
for these outcomes may lie in enhancement of D3R expression and
binding activity as a result of chronic L-DOPA treatments (Cote and
Kuzhikandathil, 2015), however there are many issue that still need to
be elucidated further regarding this hypothesis. For one, D3R binding in
ventral striatum has been shown to be lower in PD patients with ICD
compared with those without, and also correlated with the severity of
ICD (Payer et al., 2015).
Controversy between these studies also may be due to the diﬀering
genotypes of D3R. Researchers testing the association between ICD and
D3R allelic variants, showed that D3R Ser9Gly (rs6280) genotype was
signiﬁcantly associated with ICD. In patients with this genotype, it is
likely that increased D3R-ligand aﬃnity, due to the gain-of-function
conferred by the glycine residues, could impair reward-risk assessment
and ultimately lead to ICD (Krishnamoorthy et al., 2016). However,
another study discussed the association between the polymorphisms of
13 candidate genes and suggest that the independent contribution of a
single D3R polymorphism in ICD is too low to be detected (Kraemmer
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Ageing Research Reviews 57 (2020) 100994

P. Yang, et al.

Fig. 4. The relationship between D3R with
LID. Left penal: D3R exacerbates D1R hypersensitivity and leads to LID. D3R enhances
the expression of D1R in the surface of neurons, increases the aﬃnity of DA to D1R, and
activates the downstream signal pathway of
D1R, ﬁnally induces the oversensitivity of D1R,
which leads to LID. Right panel: D3R inhibition
relieves LID, but shows no eﬀect on alleviating
PD symptoms. D3R inhibition lead to the lack
of D1R in the surface of neurons and the decreased aﬃnity of DA on D1R, which induces
damaged alleviation of DA agonists in PD
symptoms. Dopamine (DA); cyclic adenosine
monophosphate (cAMP); protein kinase A
(PKA); γ-aminobutyric acid (GABA); L-DOPA
induced dyskinesias (LID).

LID occurrence (Rangel-Barajas et al., 2011). But D1R hypersensitivity
can be modulated by D3R. L-DOPA-induced D3R overexpression principally occurs in D1R-containing neurons but shows relatively lower coexpression in the D2R-containing neurons (Solis et al., 2017). That may
because D3R combines with D1R to form a heteromeric complex which
plays an important part in LID (Fiorentini et al., 2008; Solis et al.,
2017). There is a close relationship between the expression of D1R-D3R
heterodimer and the occurrence of LID (Solis and Moratalla, 2018). An
interaction between D3R and D1R could increase the binding aﬃnity
between D1R and DA, and enhance the density of D1R due to the lack of
internalization of D1R (Fanni et al., 2018). In addition, the expression
of D3R induced by long term L-DOPA treatment is instrumental in activating the downstream signal pathway of D1R, which aggravates the
oversensitivity of D1R (Azkona et al., 2014).
This proposed explanation leads to an interesting conclusion, that is,
balancing and normalizing the activation of D3R may relieve the ﬂuctuation of D1R sensitivity, thus avoiding the occurrence of LID; overactivation of D3R may induce LID, while blocking D3R activation may
lead to PD symptoms. Some studies conﬁrmed our deduction. When
D3R full agonists, such as PD128907 (Ki was 0.4 nM (Scheideler et al.,
1997)), were co-administered with D1R agonists (such as SKF38393) in
rat experiments, there were severe exacerbation of LID (Lanza et al.,
2018). When a partial agonist BP897 (Ki was 0.92 nM (Garcia-Ladona
and Cox, 2003)) was administrated to animals in combination with LDOPA, not only LID was attenuated, there was also no inﬂuence on the
therapeutic eﬀect of L-DOPA (Bezard et al., 2003). However, when a
speciﬁc D3 receptor antagonist was co-administrated with L-DOPA, LID
severity was alleviated but PD-like symptoms reappeared (Bezard et al.,
2003). The suggestion that both D3R selective antagonists and partial
agonists are pharmacotherapeutic candidates for the treatment of LDOPA-associated AIMs in patients with PD (Mela et al., 2010; Riddle
et al., 2011) can also be supported by our deduction.
Normalizing the activation of D3 receptor might attenuate LID
without aﬀecting the therapeutic eﬀect produced by L-DOPA.
Overactivation of D3R may induce LID because it enhances the density
of D1R or augments D1R activity. Inhibiting D3R totally may cause
damaged alleviation in PD symptoms due to the protective roles D3R
played in PD therapy. The best approach is to mildly activate D3R (see
Fig. 4).
This view is in accordance with animal tests and clinical practice.
SK609 (a D3R selective agonist, Ki = 103 nM (Xu et al., 2017b)) notably improved the performance of the Parkinson like symptoms but did
not induce AIMs and even reduced AIMs when co-administrated with L-

et al., 2016). Some researchers believe that the selectivity for D3R over
D2R should be taken into account and suggest that the incidence of ICD
may be related to the aﬃnity of D3R/D2R. This theory concludes that
for a medicine - the higher the aﬃnity of D3R/D2R, the higher the
proportion of ICD induced by the medicine - for a given patient population (Seeman, 2015). Other possible reasons for variable incidences of
ICD may also include: routes of administration (oral D3R agonists have
higher risk of ICD development than transdermal(Garcia-Ruiz et al.,
2014)), diﬀering dosage (high D3R agonists dosage often means high
frequency of ICD(Hassan et al., 2011)), or age of subjects (younger
people may be better able to act on their impulses than seniors (Hassan
et al., 2011)).
7. Role of D3R in treating L-DOPA induced dyskinesia
L-DOPA therapy remains the gold standard for PD treatment,
however, long term L-DOPA exposure is closed related with many side
eﬀects, among which the commonest one is L-DOPA-induced dyskinesia
(LID), or L-DOPA-induced abnormal involuntary movements
(AIMs).The incidence of LID in PD patients receiving L-DOPA treatment
for over 5 years is 50 % (Dragasevic-Miskovic et al., 2019). Investigators are therefore committed to developing new PD drugs that
will not cause LID, or drugs that can be combined with L-DOPA to reduce the onset of LID. D3R might be a target.
Some researchers believe that D3R expression is upregulated in the
LID patients receiving long-term treatment with L-DOPA (Aristieta
et al., 2012; Bezard et al., 2003; Payer et al., 2016). Not only the expression of D3R, but also the binding of D3R was higher in LID monkeys
or patients when compared to non-dyskinetic PD or normal counterparts (Guigoni et al., 2005; Payer et al., 2016), which hinted the role of
D3R in LID. The overexpression of D3R induces behavioral sensitization
in parkinsonian subjects, which subsequently leads to the occurrence of
LID when treated with L-DOPA (Guillin et al., 2001). Down-regulating
the expression of D3R in the striatum (Wang et al., 2015b), or blocking
D3R (Cote et al., 2014), reversed motor ﬂuctuations in rat PD models in
which D3R expression was elevated.
D3R selective agonists can be used for the treatment of LID (Simms
et al., 2016; Utsumi et al., 2013). However, what puzzled us is why D3R
agonists hinder the occurrence of LID when D3R elevation or activation
is believed to contribute to LID. Here is a brief explanation. Actually, it
is D1R rather than the D3R activation contribute to LID. Long term LDOPA administration may induced hypersensitivity of D1R, thus enhance GABA release and cAMP accumulation, which may play a role in
11
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and patients who carry Gly/Gly need higher doses of DR agonist to
achieve identical treatment (Xu et al., 2017a).
Determining the precise D3R genotype may help identify potential
side eﬀects of PD therapy. A study has shown that the D3R Ser/Ser
genotype is a predictor of gastrointestinal symptoms after L-DOPA
treatment (Rieck et al., 2018). Other results showed that D3R Ser/Gly
may lead to essential tremor in PD (Paus et al., 2010).

DOPA (Simms et al., 2016). Pramipexole (Ki = 10–12.6 nM (Millan
et al., 2000, 2002)) was shown to be more eﬀective than ergotamine
D1R/D2R agonists in alleviating LID when co administrated with LDOPA. It has been reported that when treated with a partial D3R
agonist, the improvement in LID is associated with a worsening of
Parkinsonism. In other words, the reduction in LID occurs at the expense of the anti-parkinsonian eﬀects of L-DOPA (Hsu et al., 2004). This
conclusion is in good agreement with our results.
Although we have shown many results that demonstrate the reliability of our conclusion, there are still some reports which give inconsistencies. Some results show no diﬀerences in striatal D3R expression
between normal and PD patients (Hurley et al., 1996). Others studies where chronic L-DOPA treatments produced AIMs - reported that cotreatment with D3R antagonist, S33084, and L-DOPA shows no alleviating eﬀect either in terms of AIM frequency or amplitude in rats
(Mela et al., 2010). Similar results were also obtained in MPTP treated
marmosets (Silverdale et al., 2004). Other inﬂuencing factors for these
results could be to blame. One, doses of D3R agonists/antagonists may
exert inﬂuence on LID presentation. One Study has shown that high
doses of D3R antagonists show a reduction of LID, while low doses do
not show such an eﬀect (Hadj Tahar et al., 1999). Two, doses of L-DOPA
may inﬂuence the D3R antagonists’ eﬀect on LID. According to the
receptor competition theory, increased dopamine induced by enhanced
doses of L-DOPA can competitively inhibit the binding of antagonist to
D3R. Therefore, the dosage of L-DOPA may aﬀect the therapeutic
beneﬁts of D3R antagonist on LID. Three, there is evidence that the
pathogenesis of PD may also change with respect to the progress of LID.
There is a hypothesis that the development of LID reﬂects D3R insensitivity in an early age and sensitivity in the later age (Mela et al.,
2010).Four, as mentioned previously, the discrepancy of D3R expression and binding state of its exogenous ligand between diﬀerent PD
stages, treatments, or species may also lead to deviations in experimental results. Lastly, we also acknowledge that in some studies, the
activation of partial D3R agonists on other receptors may also help to
relieve LID. For example, partial D3R agonist, BP897, was shown to
attenuate LID and is also believed to be a potent ligand at 5-HT receptor
(Heidbreder et al., 2005). Furthermore, activation of 5-HT also participates in alleviating LID (Bibbiani et al., 2001).
Therefore, we must mention that the hypothesis of the important
role that D3R may play in the pathogenesis of LID is only a conjecture
based on the review of the relevant literature, which we believe may
too simplistic for discussing such a common and complicated side eﬀect
of L-DOPA. We cannot explain that why LID occurs after long term
exposure to L-DOPA rather than immediately after several doses of LDOPA or why a single dose of selective D3R antagonist shows no eﬀect
upon established LID. Others posit that the chronic aggravation induced
via pathological damage, such as a loss of homeostatic synaptic plasticity in striatum or SN is also considered as a possible cause of LID
(Borgkvist et al., 2018).

9. Conclusions
For a long time, D1R and D2R have long been considered as critical
participants in PD occurrence and progression. However, with in-depth
understanding of the structure and function of D3R, people are paying
more and more attention in the role of D3R in PD. But it is diﬃcult to
develop D3R-speciﬁc tracers and agonists as D2R and D3R show high
similarity. We developed a quantitative autoradiography procedure for
measuring the densities and mapping the regional distributions of D2R
and D3R in the brain, and found that the striatal D3R is closely related
with pathophysiological symptoms and prognosis results in PD patients.
Therefore, we review the role of D3R in the pathogenesis, treatment
and prognosis of PD, and try to provide insights for novel PD pharmaceutics via targeting D3R.
By summarizing literatures, we ﬁnd that alterations of D3R involve
in the early stage of PD and may be considered as an early stage biomarker for predicting PD occurrence. D3R agonists are also thought to
be eﬃcient in the treatment of PD, with their eﬀect in increasing DA
content, decreasing α-Syn accumulation, enhancing BDNF secretion,
ameliorating oxidative stress and neuroinﬂammation, promoting neurogenesis and interacting with other DRs. Besides, Targeting D3R also
helps in relieving some PD associated non motor symptoms and side
eﬀects of L-DOPA. Furthermore, D3R is also considered as an indicator
for predicting prognosis of PD treatment. All of these suggested that
D3R may be of great importance in the diagnosis, treatment and
prognosis of PD. However, many questions need further clariﬁcation.
1 Whether the development of highly selective tracers or drugs for
D3R will yield better diagnostic or therapeutic eﬀects without unwanted side eﬀects. We should avoid similar phenomena as valdecoxib, a highly selective inhibitor of COX2 with strong anti-inﬂammatory eﬀects, which was unfortunately withdraw from the
market due to severe cardiovascular side eﬀects (Atukorala and
Hunter, 2013).
2 Should the interactions between D3R and other GPCRs or other
related proteins be taken into account in the diagnosis and treatment of PD? Our literature review indicates that interactions between D3R and other GPCRs or other related proteins (such as
VMAT2) may be an important factor in the occurrence and development of PD, rather than D3R itself.
3 As mentioned earlier, D3R activation not only participates in the
treatment of PD, but also help in alleviating the occurrence of LID.
Both eﬀects are achieved partly by regulating D1R activity. The
critical questions are what’s the ideal aﬃnity and selectivity of D3R
agonists and what’s the optimized individual dosage in clinical
practice?

8. D3R changes for predicting prognosis of PD treatment
The change in D3R expression or function helps predict prognosis of
PD treatment. For example, it was suggested that if D3R is elevated,
response to DAergic drugs will be maintained. Correspondingly, loss of
D3R density correlated with loss of response to DAergic drugs (Joyce
et al., 2002). In an animal study, DR agonists showed better improvement in alleviating PD symptoms in animals with striatal over-expression of both D2R and D3R, when compared to those with over-expression of only D2R (Matsukawa et al., 2007).
However, most studies focus on D3R genotype in determining
treatment plans. Changes in a single residue in D3R may cause ﬂuctuation in agonist-dependent tolerance property (Gil-Mast et al., 2013),
and aﬀect the therapeutic eﬀect of related drugs. In D3R, the most
commonly researched polymorphic site is Ser9Gly. A study showed that
D3R Ser/Gly mutant is the main factor determining dose of DR agonists,

Although much scientiﬁc research is needed to further reveal the
roles of D3R in PD, we believe that the development of D3R speciﬁc
tracers and drugs is important for the diagnosis and treatment of PD.
While we do not expect D3R-related drugs will solve all the problems,
each step of understanding D3R will bring us closer to an improved cure
for PD.
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